On 20 March 2017, orphan designation (EU/3/17/1855) was granted by the European Commission to GW Research Ltd, United Kingdom, for cannabidiol for the treatment of Lennox-Gastaut syndrome.
The sponsorship was transferred to GW Pharma (International) B.V., the Netherlands, in April 2019.
Cannabidiol for treatment of Dravet syndrome and treatment of Lennox-Gastaut has been authorised in the EU as Epidyolex since 19 September 2019.
|Disease / condition||
Treatment of Lennox-Gastaut syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.